Skip to main content

Severe Acute Respiratory Syndrome clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for
  • A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

    Sorry, not currently recruiting here

    The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen therapy with or without mechanical ventilation. It is thought that COVID-19 activates the complement system, part of the immune system that responds to infection or tissue damage, and increases inflammation in the lungs. APL-9 has been designed to inhibit or block activation of part of the complement pathway, and potentially reduce inflammation in the lungs. Part 1 of the study is open-label to evaluate safety; all participants will receive APL-9 plus standard of care. Part 2 of the study is double-blind, randomized; participants will receive either APL-9 or the vehicle-control plus standard of care.

    Fresno, California and other locations

Last updated: